-
Press Release
TEST ROOT1 Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU)
-
Press Release
Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU)
-
Press Release
Novartis to launch Direct-to-Patient platform for Cosentyx® (secukinumab) in the US
-
Press Release
Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease
-
Press Release
Novartis provides update on Phase III GCAptAIN study of Cosentyx® in giant cell arteritis (GCA)
-
Press Release
Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN)
-
Press Release
FDA approves Novartis radioligand therapy Pluvicto® for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer
-
Press Release
New Novartis Phase III data demonstrate meaningful efficacy and safety results of intrathecal onasemnogene abeparvovec in broad patient population with SMA
-
Press Release
Novartis data presentations at AAAAI and AAD underscore commitment to advancing treatment of hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU)
-
Press Release
Novartis bolsters late-stage cardiovascular pipeline with agreement to acquire Anthos Therapeutics for USD 925 million upfront
-
Press Release
Novartis Entresto® US patent upheld by US Court of Appeals
-
Press Release
Longer-term Novartis Kisqali® NATALEE data show durable reduction in distant recurrence in broad population of patients with early breast cancer